Ergomed PLC (LON:ERGO) had its price target lifted by research analysts at Numis Securities Ltd from GBX 280 ($3.72) to GBX 300 ($3.99) in a research note issued to investors on Monday. The brokerage currently has a “buy” rating on the stock. Numis Securities Ltd’s price target points to a potential upside of 51.13% from the stock’s current price.

Shares of Ergomed PLC (LON ERGO) opened at 223.49 on Monday. The firm’s market cap is GBX 90.59 million. Ergomed PLC has a 12-month low of GBX 122.00 and a 12-month high of GBX 225.00. The company has a 50-day moving average of GBX 177.60 and a 200 day moving average of GBX 190.98.

Ergomed PLC (LON:ERGO) last posted its quarterly earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share for the quarter. The company had revenue of GBX 2,291 million for the quarter. Ergomed PLC had a net margin of 2.07% and a return on equity of 2.69%. Equities research analysts anticipate that Ergomed PLC will post $7.80 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Ergomed PLC (ERGO) PT Raised to GBX 300 at Numis Securities Ltd” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at

About Ergomed PLC

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with's FREE daily email newsletter.